About Exelixis, Inc. (EXEL)

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharma

EXEL Key Statistics

EXEL Price Performance

Exelixis, Inc. stock has returned -0.98% over the past day, -6.78% over the past week, -3.33% over the past month, and -6.35% over the past three months. The stock trades between a 52-week low of $32.38 and a high of $49.62.

EXEL Financial Fundamentals

Exelixis, Inc. reports a return on equity (ROE) of +35.53%, operating margin of +38.48%, profit margin of +3372.96%, and revenue growth of +685.00%. The debt-to-equity ratio is 0.09. Current ratio stands at 3.56.

EXEL Earnings

Exelixis, Inc.'s next earnings report is expected on 2026-05-12 (68 days away). The company has a +1.00% earnings beat rate with an average surprise of +19.83%. Earnings consistency is rated as "high".

EXEL Ownership

Institutional investors hold approximately +1.03% of EXEL shares across 10 institutions. Insider ownership is +0.02%. Insider sentiment is "bearish".

EXEL Short Interest

EXEL has a short interest of +15.51% of float with a short ratio (days to cover) of 11.2.

EXEL AI Analysis Signal

iGotFomo's AI-powered signal engine rates EXEL as "HOLD" with LOW confidence (score: 29/100). 6 signals are bullish, 5 are bearish, and 2 are neutral.